Price
$79.86-11.43%Social Signal Score
Analyst Ratings
27 analysts52-week range
- Last close
- $79.86
- Off 52w high
- -11.4%
- 200-day average
- $72.71
- vs 200-day
- +9.8%
Revenue
$222.44MAnalyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Neil Kumar
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 999
- Beta
- 0.97
- Country
- US
- Piotroski score
- 3 / 9 (Weak)
- Altman Z-score
- -3.57
Financials
Revenue
$222.44M+731.8%Net Income
$-152.22MEBITDA
$-136.63MFree Cash Flow
$-71.54MEPS (diluted)
$-0.78Shares Outstanding (diluted)
195.79M+112.0%Operating Expenses
$335.71MCash & Debt
$720.16MReturn of Capital
$131.77MRevenue by Segment (annual)
$502.08MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $502.08M | $-729.31M | $-3.79 |
| 2024 | $221.90M | $-535.76M | $-2.88 |
| 2023 | $9.30M | $-643.20M | $-3.95 |
| 2022 | $77.65M | $-481.18M | $-3.35 |
| 2021 | $69.72M | $-562.54M | $-3.90 |
| 2020 | $8.25M | $-448.72M | $-4.10 |
| 2019 | $40.56M | $-260.44M | $-2.48 |
| 2018 | $0.00 | $-130.75M | $-1.42 |
| 2017 | $0.00 | $-30.57M | $-0.33 |
Valuation
BBIOhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
83-32.43%Social Signal Score
Mentions (28)
- Newsseekingalpha.com·12d ago·Positive
BridgeBio Pharma, Inc. (BBIO) Presents at Bernstein Insights: Healthcare Leaders and Disruptors - 3rd Annual Healthcare Forum Transcript BridgeBio Pharma, Inc. (BBIO) Presents at Bernstein Insights: Healthcare Leaders and Disruptors - 3rd Annual Healthcare Forum Transcript
View source ↗ - Newsglobenewswire.com·13d ago·Negative
Acoramidis Demonstrates Real-World Benefit Versus Tafamidis in ATTR-CM, Reducing Risk of Clinical Worsening - In the first peer-reviewed, real-world, contemporary, comparative effectiveness study of TTR stabilizers in ATTR-CM using U.S. claims data, acoramidis was associated with a statistically and clinically significant 34% reduction in a composite of clinical worsening events (diuretic intensification, heart failure hospitalization, and mortality) versus tafamidis (p=0.046), supporting improv
View source ↗ - News (RSS)seekingalpha·20d ago·Positive
BridgeBio Pharma, Inc. (BBIO) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
View source ↗ - Newsseekingalpha.com·20d ago·Positive
BridgeBio Pharma, Inc. (BBIO) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript BridgeBio Pharma, Inc. (BBIO) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
View source ↗ - News (RSS)yahoo·24d ago·Neutral
BridgeBio Oncology Therapeutics (BBOT) Bets Big On A Narrower KRAS Playbook
View source ↗ - Newsseekingalpha.com·25d ago·Positive
BridgeBio Pharma, Inc. (BBIO) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Transcript BridgeBio Pharma, Inc. (BBIO) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Transcript
View source ↗ - Newsseekingalpha.com·26d ago·Positive
BridgeBio Pharma: Attruby Peak Sales Set To Rise BridgeBio pharma has delivered multiple clinical and commercial successes, yet shares have repeatedly sold off after positive catalysts. Infigratinib's dwarfism trial outperformed the market leader, and Attruby continues to beat sales estimates, with management now guiding higher peak sales. Recent competitor setbacks and new data on Attruby's kidney benefits and hospital day reduction further strengthen BBIO's commercial outlook.
View source ↗ - Newsseekingalpha.com·26d ago·Positive
BridgeBio Pharma, Inc. (BBIO) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript BridgeBio Pharma, Inc. (BBIO) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
View source ↗ - Newszacks.com·26d ago·Neutral
BridgeBio Pharma (BBIO) Down 10.7% Since Last Earnings Report: Can It Rebound? BridgeBio Pharma (BBIO) reported earnings 30 days ago. What's next for the stock?
View source ↗ - News (Marketaux)manilatimes.net·27d ago·Positive
Oral Infigratinib Shows Meaningful Benefits Beyond Growth Within 52 Weeks in Children with Achondroplasia in the Phase 3 PROPEL 3 Trial ., Sept. 09, 2026 (GLOBE NEWSWIRE) -- <e[+47 characters]
View source ↗ - Newsglobenewswire.com·27d ago·Positive
Oral Infigratinib Shows Meaningful Benefits Beyond Growth Within 52 Weeks in Children with Achondroplasia in the Phase 3 PROPEL 3 Trial - Treatment with oral infigratinib for 52 weeks in PROPEL 3 resulted in favorable trends against placebo in clinically meaningful exploratory endpoints including sleep apnea and otitis media events
View source ↗ - Newsglobenewswire.com·34d ago·Negative
…inib on Medical Complications in Achondroplasia at the Annual ESPE Meeting 2026 PALO ALTO, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage, multi-product biopharmaceutical company focused on developing medicines for genetic conditions, announced today that one late-breaking oral presentation on the impact of oral infigratinib on medical complications in achondroplasia from PROPEL 3 will be shared at the Annual Eu…
View source ↗ - Newsglobenewswire.com·35d ago·Neutral
BridgeBio to Participate in September Investor Conferences PALO ALTO, Calif., Sept. 01, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage, multi-product biopharmaceutical company focused on developing medicines for genetic conditions, today announced that members of its management team will participate in fireside chats at the following healthcare investor conferences:
View source ↗ - Newsglobenewswire.com·35d ago·Negative
BridgeBio Announces Agreement with U.S. Government to Improve Affordability and Access to Critical Medicines for Americans - This voluntary agreement expands access for Medicaid patients to BridgeBio's currently marketed medicine and lowers drug costs for Americans without jeopardizing innovation and sustainability in rare diseases
View source ↗ - Newsglobenewswire.com·36d ago·Positive
Acoramidis Demonstrates Reversal of Cardiac Structural Disease Progression and Functional Decline and Significantly Increases Days Alive and Free from Hospitalization in ATTR-CM - Acoramidis is the first therapy shown to potentially reverse cardiac structural disease progression and functional decline through 42 months based on CMR imaging, with up to half of patients showing clinically meaningful improvement in cardiac function in the completer analysis - Patients treated with acoramidis were
View source ↗ - Newsglobenewswire.com·41d ago·Neutral
BridgeBio Announces First Participant Dosed in ASCEND-ATTR, a Phase 3b/4 Study Evaluating the Long-Term Effects of Acoramidis on Disease Regression in ATTR-CM - The ASCEND-ATTR study builds on the Phase 3 ATTRibute-CM CMR substudy results previously shared here, which indicated treatment with acoramidis may improve cardiac structure and function with evidence of amyloid regression in a subset of patients
View source ↗ - Newszacks.com·41d ago·Negative
BridgeBio Q2 Sales Jump 120% as Attruby Drives Commercial Momentum BBIO's Q2 sales jump 120% as Attruby drives growth, while higher spending widens the loss and raises the stakes for 2026.
View source ↗ - Newszacks.com·41d ago·Positive
Why BBIO Rose 24% in Three Months and Whether the Rally Can Continue BridgeBio's 24% three-month rally faces a higher bar as Attruby growth and pipeline catalysts compete with valuation and execution risks.
View source ↗ - Newszacks.com·41d ago·Negative
Is BBIO a Buy as Fast Sales Growth Meets a Steep Valuation Premium? BridgeBio's fast-growing Attruby sales and pipeline expansion face a steep valuation premium, continued losses and launch risks.
View source ↗ - Newsglobenewswire.com·43d ago·Positive
…oramidis Data from Open-Label Extension Analyses in ATTR-CM at ESC Congress 2026 PALO ALTO, Calif., Aug. 24, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a biopharmaceutical company focused on developing medicines for genetic conditions, announced today that two oral presentations and three posters on new acoramidis data in individuals with transthyretin amyloid cardiomyopathy (ATTR-CM) will be shared at the European Society of Cardiology (ESC) C…
View source ↗ - Newsglobenewswire.com·53d ago·Negative
… the Company's shareholder base toward further high-quality, long-term ownership PALO ALTO, Calif., Aug. 14, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio”), a commercial-stage, multi-product biopharmaceutical company focused on developing medicines for genetic conditions, announced today the pricing of a secondary offering of 5,000,000 shares of its common stock by the selling stockholder KKR Genetic Disorder L.P.
View source ↗ - News (Marketaux)manilatimes.net·53d ago·Neutral
BridgeBio Pharma Announces Launch of Secondary Offering of Common Stock on Behalf of an Existing Shareholder ., Aug. 13, 2026 (GLOBE NEWSWIRE) -- <em[+46 characters]
View source ↗ - Newsglobenewswire.com·53d ago·Negative
…aunch of Secondary Offering of Common Stock on Behalf of an Existing Shareholder PALO ALTO, Calif., Aug. 13, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio”), a commercial-stage, multi-product biopharmaceutical company focused on developing medicines for genetic conditions, announced today the launch of a secondary public offering of 5,000,000 shares of its common stock by the selling stockholder KKR Genetic Disorder L.P. The Company is not selling any shares and will…
View source ↗ - Newszacks.com·55d ago·Neutral
BridgeBio Q2 Earnings Miss, Revenues Beat as Attruby Sales Surge BBIO's Q2 loss misses estimates, but revenues beat expectations as Attruby sales more than tripled, fueling growth and pipeline advances.
View source ↗ - Newsseekingalpha.com·55d ago·Neutral
BridgeBio: Attruby Delivers In Q2, Expect Three New Launches In 12 Months BridgeBio (BBIO) delivered a Q2 beat, reaffirmed $1B+ 2026 Attruby/Beyonttra global sales guidance, and expectations for three product launches by mid-2027. Attruby's U.S. net sales surged 311% Y/Y, with ex-U.S. Beyonttra royalties up 62% sequentially as they continue to gain TTR stabilizer market share. BBIO's $1B preferred equity raise addresses balance sheet concerns, supporting accelerated commercial and pipeline inves
View source ↗ - Newsseekingalpha.com·56d ago·Positive
BridgeBio Pharma, Inc. (BBIO) Q2 2026 Earnings Call Transcript BridgeBio Pharma, Inc. (BBIO) Q2 2026 Earnings Call Transcript
View source ↗ - Newszacks.com·56d ago·Negative
BridgeBio Pharma (BBIO) Reports Q2 Loss, Tops Revenue Estimates BridgeBio Pharma (BBIO) came out with a quarterly loss of $0.78 per share versus the Zacks Consensus Estimate of a loss of $0.64. This compares to a loss of $0.95 per share a year ago.
View source ↗ - Newsmarketbeat.com·56d ago·Positive
BridgeBio Pharma Q2 Earnings Call Highlights BridgeBio Pharma NASDAQ: BBIO reported continued growth for its ATTR cardiomyopathy treatment Attruby in the second quarter of 2026, while advancing three late-stage programs into regulatory review and expanding commercial preparations for potential launches over the next year.
View source ↗
Earnings
Wed, Oct 28(in 3 weeks)
Consensus estimate $-0.61 per share
Typical surprise -20.2% (median, so one quarter with a near-zero estimate can't distort it)
- Mon, Aug 10$-0.78 vs $-0.58miss
- Thu, May 7$-0.84 vs $-0.68miss
- Tue, Feb 24$-1.00 vs $-0.71miss
- Wed, Oct 29$-0.95 vs $-0.88miss
- Tue, Aug 5$-0.95 vs $-0.83miss
- Tue, Apr 29$-0.88 vs $-1.00beat
Estimates and results for BBIO via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by BBIO officers and directors.
- Bought
- —
- Sold
- $36.4m
0 trades
40 trades
- Kumar Neilsold
- Kumar Neilsold
- Kumar Neilsold
- Kumar Neilsold
- Kumar Neilsold
- Kumar Neilsold
- Kumar Neilsold
- Kumar Neilsold
60 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
- Gilbert Ray Cisneroshouse · CA31 · disclosed Jun 9, 2026 (29d later)Buy$1,001 - $15,000
- Gilbert Ray Cisneroshouse · CA31 · disclosed May 11, 2026 (12d later)Buy$1,001 - $15,000
- Gilbert Ray Cisneroshouse · CA31 · disclosed Apr 8, 2026 (36d later)Buy$1,001 - $15,000
- Gilbert Ray Cisneroshouse · CA31 · disclosed Apr 8, 2026 (20d later)Buy$1,001 - $15,000
- Gilbert Ray Cisneroshouse · CA31 · disclosed Apr 8, 2026 (21d later)Buy$1,001 - $15,000
- Gilbert Ray Cisneroshouse · CA31 · disclosed Oct 10, 2025 (18d later)Buy$1,001 - $15,000
- Gilbert Ray Cisneroshouse · CA31 · disclosed Sep 12, 2025 (35d later)Buy$1,001 - $15,000
Self-reported filings, amounts as brackets. Via Senate/House disclosures.